Rowlandmiller & PARTNERS.ADV Takes $107,000 Position in Cryo-Cell International, Inc. (NYSEAMERICAN:CCEL)

Rowlandmiller & PARTNERS.ADV acquired a new stake in Cryo-Cell International, Inc. (NYSEAMERICAN:CCEL) during the 4th quarter, HoldingsChannel.com reports. The institutional investor acquired 14,433 shares of the company’s stock, valued at approximately $107,000.

Separately, Geode Capital Management LLC boosted its holdings in shares of Cryo-Cell International by 68.5% in the 3rd quarter. Geode Capital Management LLC now owns 39,860 shares of the company’s stock worth $254,000 after acquiring an additional 16,203 shares in the last quarter. Institutional investors own 10.44% of the company’s stock.

Cryo-Cell International Stock Performance

Shares of CCEL opened at $7.71 on Monday. The company has a market capitalization of $62.14 million, a PE ratio of -7.27 and a beta of 0.53. Cryo-Cell International, Inc. has a one year low of $4.47 and a one year high of $9.50.

Cryo-Cell International Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, February 28th. Stockholders of record on Friday, February 14th will be issued a $0.25 dividend. This represents a $1.00 annualized dividend and a dividend yield of 12.97%. The ex-dividend date of this dividend is Friday, February 14th. Cryo-Cell International’s payout ratio is currently -94.34%.

Cryo-Cell International Profile

Cryo-Cell International, Inc engages in the cellular processing and cryogenic cellular storage with a focus on the collection and preservation of umbilical cord blood stem cells for family use. It provides cord tissue service that stores a section of the umbilical cord tissue, a source of mesenchymal stem cells that are used in regenerative medicine to treat a range of conditions, including heart, and kidney disease, ALS, wound healing, auto-immune diseases, multiple sclerosis, Alzheimer's disease, Parkinson's diseases.